Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen


One might think that celebrity endorsements would be fantastic for the share price of a small or microcap company. After all, famous and successful athletes or movie stars have a stack of cash to invest and the connections to help accelerate business developments. Oddly, though, it doesn’t seem to have a great deal of impact. Even sports legends Shaquille O’Neal and Reggie Jackson being onboard as both investors and brand ambassadors to Soupman, inc. (OTCQB: SOUP) haven’t lifted shares. In fact, shares actually slipped lower after announcing Shaq, one of the biggest names in basketball history and a promotional wizard, in late 2011.

Surely hoping that the announcement of a new star partner will have a more beneficial impact on market valuation is Digital Development Group Corp. (OTCBB: DIDG) with Wednesday evening’s report that actor Charlie Sheen has joined the team. The Hollywood-based company is involved in acquisition and distribution of Over the Top, or “OTT,” television content.

OTT content is, in short, the broadband delivery of video or audio by a third party (meaning that the Internet service provider is not involved in the control or distribution of the content) that is accessible through multiple internet-connected mediums. It is steadily gaining traction as consumers continue to utilize more mobile devices, smart TVs, connected DVD players, game consoles and devices like Roku to meet their demands to control what they watch free of constraints of traditional cable programming packages and, often times, commercials. Household names in the OTT industry include Netflix (NASDAQ: NFLX) and Hulu.

Obviously, big-budget companies like Netflix and Hulu tailor their business towards distribution of mainstream programs and movies, but smaller companies like DigiDev, as it is often called, are initially focused on creating original content for its growing library of material. For a small fee, the company currently offers access to collections through channels such as its “Sci-Fi Station” with cult classics in horror, science fiction, etc. and “Synapse Films,” which contains a wide array of “features, documentaries and clips…be it weird, offbeat, cult, sexy, exploitation, B movies, or other strange and unusual titles,” to name a few.

Future offerings include channels featuring people like Kato Kaelin, made famous as a witness in the O.J. Simpson murder trial, former porn star (and vice presidential candidate) Marilyn Chambers, and now Charlie Sheen.

Sheen, the son of Hollywood icon Martin Sheen and brother of actor Emilio Estevez, has made a positive name for himself as a star in blockbuster movies such as Platoon and Wall Street and TV show Two and a Half Men, but also has had his personal life criticized with reports of alcohol and drug abuse as well as alleged domestic violence.

Describing his company as “misfits of TV,” DigiDev president Joe Q. Bretz, says that he has been working with Sheen for “quite some time” to ink the new partnership. Bretz explained that “misfits change the world, and we intend on creating something alongside Charlie that will be historical.”

“A long time ago on a movie set far, far away, a character I once played said, ‘life all comes down to a few moments, and this is one of them,’” commented Sheen in the corporate statement. “DigiDev is one of these moments. For years I have longed for a home and an outlet for the tsunami that is my brain. Batten down the Forbes hatches; I hope DigiDev can hold its breath for a long time.”

Sheen will serve as curator of DigiDev’s channels and as an advisor for special content acquisitions, according to the company. No filings with the SEC have been made as of the time of this writing to sift through for more details of the contract.

From the investor side, traders will be watching on Thursday to see if the news can make a splash. Shares of DIDG have been on the slide since it began trading in April 2012 around $1.30 per share, closing Wednesday at 8.5 cents, for gains of 10.4 percent on the day.

Shares had sunk as low as 5 cents in January, before spiking to 20.5 cents about two weeks later. Will this be the kick it needs for the stock to identify the nickel mark as a true bottom and start a new uptrend? Well, only time will deliver that answer, but this is an interesting development for fans of DigiDev and Hollywood’s bad boy. Proper due diligence is, as always, encouraged.

Article submitted by

Digital Development Group (DIDG) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally - and taking the headline - the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.